EULAR updates rheumatoid arthritis treatment recommendations :- Medznat

EULAR releases updated rheumatoid arthritis management guidelines

Font Size

The European Alliance of Associations for Rheumatology (EULAR) has revised its recommendations for rheumatoid arthritis (RA) treatment to reflect emerging evidence regarding the effectiveness, safety profile, and cost of disease-modifying antirheumatic drugs (DMARDs). An international task force carried out two systematic literature reviews and explored the evidence against the 2022 recommendations. The updated guidance retains five overarching principles and consolidates treatment guidance into nine recommendations.

The nine recommendations are as follows:

Initiate treatment early: Commence DMARD therapy as soon as RA is diagnosed.
Target sustained disease control: Aim for sustained remission or, when appropriate, low disease activity in every patient.
Monitor disease activity and adjust treatment: Assess active disease every 1–3 months. Adjust therapy if there is no improvement within 3 months or if the treatment target has not been attained by 6 months. After the treatment target is consistently maintained, follow-up monitoring may be performed at longer intervals.
Prioritise methotrexate (MTX): Include MTX in the initial treatment strategy. Leflunomide or sulfasalazine may be considered when MTX is contraindicated or poorly tolerated early in treatment.
Use glucocorticoids for short term: Consider short-term glucocorticoids when initiating or changing conventional synthetic DMARDs (csDMARDs), but taper and discontinue them as promptly as clinically feasible.
Escalate treatment when the target is not attained: Add a biological DMARD (bDMARD) if the csDMARD strategy fails to attain the treatment target. Janus kinase (JAK) inhibitors may be considered following an individualized assessment of safety concerns, particularly the risks of major adverse cardiovascular events (MACEs), cancer, and thromboembolic complications.
Prefer combination therapy where appropriate: Combine bDMARDs or targeted synthetic DMARDs (tsDMARDs) with a csDMARD. For those unable to take a csDMARD alongside their treatment, interleukin-6 (IL-6) pathway inhibitors and JAK inhibitors may offer advantages over some other bDMARDs.
Switch treatment after failure: If a bDMARD or tsDMARD fails, consider another agent. Following failure of a tumor necrosis factor (TNF) inhibitor or an IL-6 receptor inhibitor, clinicians may switch to a drug with a different mechanism of action or use another agent targeting the same pathway.
Consider dose reduction after sustained remission: Once glucocorticoids have been discontinued and remission is sustained, continuing DMARD therapy is suggested. Dose reduction may be considered, but stopping treatment altogether requires caution because disease flares can occur.

Overall, the recommendations reinforce a treat-to-target strategy that prioritizes early intervention, regular evaluation of disease activity, and timely treatment adjustments. MTX remains central to initial therapy, while bDMARDs and JAK inhibitors offer options when treatment goals are not met. JAK inhibitor selection requires prudent consideration of cardiovascular, malignancy, and thromboembolic risks. The guidance also supports individualized treatment decisions that account for comorbidities, safety, patient preferences, and costs.

Can incretin hormones influence metabolism even when the pancreas—the primary site of their insulin-stimulating action—is absent? Nov...

Medznat, an initiative of Dr. Reddy's Laboratories Ltd., is a resource for practicing doctors to enable their continuous learning. It provides unbiased and relevant medical information, apart from several other useful resources to aid their daily practice.

Medznat presents current medical information from the world's leading sources - the largest databases PubMed and DOAJ. Translation of articles made by ABBYY-LS.

The scientific editors of the Medznat website make sure that our publications are accurate, simple and useful to the readers. We are always glad for your questions or suggestions!

Categories

EULAR releases updated rheumatoid arthritis management guidelines

What's new?

Source:

Link:

Article:

Authors:

Comments (0)

Recommendations

Related Content

Next

Change Password!

Reset Password!

Reset Password!

Knowledge to Practice

Help Support

EULAR releases updated rheumatoid arthritis management guidelines

What's new?

Source:

Link:

Article:

Authors:

Comments (0)

Recommendations

Related Content

Related Tags

Next

Are you 21+ or a valid medical marijuana patient?